ATNM ▲ +0.6% - Actinium Pharmaceuticals, Inc.
$ATNM ATNM ATNM - Actinium Pharmaceuticals to Highlight First-in-Human Phase 1 Study of ATNM-400 a HER3-Targeted Non-PSMA Radiotherapy in Prostate Cancer at ESMO 2026
23-OCT-2026 08:00 AM ET
Share this post
More filings for $ATNM
ATNM ▲ +0.7% - Actinium Pharmaceuticals, Inc.Nov 9, 2026ATNM ▲ +2.8% - Actinium Pharmaceuticals, Inc.Nov 4, 2026ATNM ▲ +2.8% - Actinium Pharmaceuticals, Inc.Nov 4, 2026ATNM ▼ -3.3% - Actinium Pharmaceuticals, Inc.Oct 30, 2026ATNM ▲ +3.0% - Actinium Pharmaceuticals, Inc.Oct 20, 2026ATNM ▲ +0.9% - Actinium Pharmaceuticals, Inc.Oct 19, 2026
View full $ATNM filing history →💬 Comments
Loading comments…
Leave a comment